Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors.
paper
Cited
Public
- Authors
- Mascia, Paola; Pistis, Marco; Justinova, Zuzana; Panlilio, Leigh V; Luchicchi, Antonio; Lecca, Salvatore; Scherma, Maria; Fratta, Walter; Fadda, Paola; Barnes, Chanel; Redhi, Godfrey H; Yasar, Sevil; Le Foll, Bernard; Tanda, Gianluigi; Piomelli, Daniele; Goldberg, Steven R
- Year
- 2011
- Journal
- Biological psychiatry
- PMID
- 20801430
- DOI
- 10.1016/j.biopsych.2010.07.009
- PMCID
- PMC2994947
BACKGROUND: Recent findings indicate that inhibitors of fatty acid amide hydrolase (FAAH) counteract the rewarding effects of nicotine in rats. Inhibition of FAAH increases levels of several endogenous substances in the brain, including the endocannabinoid anandamide and the noncannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide, which are ligands for alpha-type peroxisome proliferator-activated nuclear receptors (PPAR-Ξ±). Here, we evaluated whether directly acting PPAR-Ξ± agonists can modulate reward-related effects of nicotine. METHODS: We combined behavioral, neurochemical, and electrophysiological approaches to evaluate effects of the PPAR-Ξ± agonists [[4-Chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid (WY14643) and methyl oleoylethanolamide (methOEA; a long-lasting form of OEA) on 1) nicotine self-administration in rats and squirrel monkeys; 2) reinstatement of nicotine-seeking behavior in rats and monkeys; 3) nicotine discrimination in rats; 4) nicotine-induced electrophysiological activity of ventral tegmental area dopamine neurons in anesthetized rats; and 5) nicotine-induced elevation of dopamine levels in the nucleus accumbens shell of freely moving rats. RESULTS: The PPAR-Ξ± agonists dose-dependently decreased nicotine self-administration and nicotine-induced reinstatement in rats and monkeys but did not alter food- or cocaine-reinforced operant behavior or the interoceptive effects of nicotine. The PPAR-Ξ± agonists also dose-dependently decreased nicotine-induced excitation of dopamine neurons in the ventral tegmental area and nicotine-induced elevations of dopamine levels in the nucleus accumbens shell of rats. The ability of WY14643 and methOEA to counteract the behavioral, electrophysiological, and neurochemical effects of nicotine was reversed by the PPAR-Ξ± antagonist 1-[(4-Chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-a,a-dimethyl-5-(1-methylethyl)-1H-Indole-2-propanoic acid (MK886). CONCLUSIONS: These findings indicate that PPAR-Ξ± might provide a valuable new target for antismoking medications.
No figures extracted from this document.
1β20 of 33
Next β
| Name | Type |
|---|---|
| 1549 local | cohort |
| 27B local | cohort |
| 30A local | cohort |
| 34A local | cohort |
| 39B local | cohort |
| 431 local | cohort |
| 441 local | cohort |
| 5045 local | cohort |
| 577 local | cohort |
| 70F7 local | cohort |
| acetic acid | drug |
| alcohol self-administration | phenotype |
| anandamide | drug |
| BP897 local | drug |
| burst firing | phenotype |
| cannabinoid CB1 receptors local | gene |
| cholinergic neurotransmission | drug |
| Chrnb2 | gene |
| cocaine | phenotype |
| Cocaine HCl local | drug |
| cocaine self-administration | phenotype |
| conditioned place preference | phenotype |
| conditioned place-preference local | phenotype |
| cortex | anatomy |
| cues local | drug |
| dopamine | drug |
| dopamine elevation in nucleus accumbens shell local | phenotype |
| dopamine level | phenotype |
| dopamine levels in nucleus accumbens shell local | phenotype |
| dopamine neuron excitation in ventral tegmental area local | phenotype |
| dopaminergic neurons | anatomy |
| electrophysiological effects of nicotine local | phenotype |
| excitation of dopamine neurons local | phenotype |
| FAAH | gene |
| FAAH-inhibiting drug local | drug |
| FAAH inhibitors local | drug |
| firing rate local | phenotype |
| food intake | phenotype |
| food pellet | drug |
| food reinforcement local | phenotype |
| genistein local | drug |
| glutamate | drug |
| hippocampus | anatomy |
| interoceptive effects of nicotine local | phenotype |
| learning and memory | phenotype |
| medial prefrontal cortex | anatomy |
| medulla | anatomy |
| Mesolimbic dopamine local | phenotype |
| mesolimbic dopamine transmission local | anatomy |
| methanandamide local | drug |
| methOEA local | drug |
| MethOEA local | drug |
| midbrain | anatomy |
| MK886 local | drug |
| monkeys | cohort |
| motor activity | phenotype |
| nicotine | drug |
| nicotine dependence | phenotype |
| nicotine discrimination local | phenotype |
| nicotine-induced dopamine elevation local | phenotype |
| nicotine-induced excitation of dopamine neurons local | phenotype |
| nicotine-induced reinstatement local | phenotype |
| nicotine reinstatement local | phenotype |
| nicotine reward | phenotype |
| nicotine seeking local | phenotype |
| nicotine-seeking local | phenotype |
| nicotine-seeking reinstatement local | phenotype |
| Nicotine-seeking response local | phenotype |
| nicotine self administration local | phenotype |
| nicotine self-administration | phenotype |
| nicotine use | phenotype |
| nicotinic acetylcholine receptor | drug |
| nucleus accumbens | anatomy |
| nucleus accumbens shell | anatomy |
| Oleoylethanolamide | drug |
| olfactory tubercle | anatomy |
| PEA | drug |
| Pontamine sky blue local | drug |
| PPARA | gene |
| PPAR-Ξ± local | drug |
| PPAR-Ξ± agonist local | drug |
| PPAR-Ξ± agonists local | drug |
| rats | cohort |
| Reinforcing properties of nicotine | phenotype |
| reinstatement | phenotype |
| relapse | phenotype |
| rimonabant | drug |
| Saimiri sciureus local | cohort |
| saline | drug |
| serotonin | drug |
| Sprague-Dawley rats | cohort |
| squirrel monkeys | cohort |
| substantia nigra | anatomy |
| tobacco dependence | phenotype |
| tyrosine kinases local | drug |
| URB597 | drug |
| ventral tegmental area | anatomy |
| VTA | anatomy |
| WY14643 local | drug |
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Cannabinoid-based Pharmacology for the Management of Substance Use Disorders. | LujΓ‘n MΓ et al. | β | 2026 | β |
| Docosahexaenoic acid provides a protective effect in amygdala-kindled rats by activating peroxisome proliferator-activated receptor Ξ±. | Gavzan H et al. | β | 2025 | β |
| Melanin-Concentrating Hormone (MCH): Role in Mediating Reward-Motivated and Emotional Behavior and the Behavioral Disturbances Produced by Repeated Exposure to Reward Substances. | Karatayev O et al. | β | 2025 | β |
| Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. | Mock ED et al. | β | 2023 | β |
| Association Between Fatty Acid Amide Hydrolase and Alcohol Response Phenotypes: A Positron Emission Tomography Imaging Study With [<sup>11</sup>C]CURB in Heavy-Drinking Youth. | Best LM et al. | β | 2023 | β |
| Effects of Ξ² -caryophyllene, A Dietary Cannabinoid, in Animal Models of Drug Addiction. | Asth L et al. | β | 2023 | β |
| New medications development for smoking cessation. | Lengel D et al. | β | 2023 | β |
| Oleoylethanolamide attenuates cocaine-primed reinstatement and alters dopaminergic gene expression in the striatum. | GonzΓ‘lez-Portilla M et al. | β | 2023 | β |
| Oleoylethanolamide attenuates the stress-mediated potentiation of rewarding properties of cocaine associated with an increased TLR4 proinflammatory response. | GonzΓ‘lez-Portilla M et al. | β | 2023 | β |
| PPARΞ± and PPARΞ³ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice | Xi Z et al. | β | 2023 | β |
| PPARΞ± and PPARΞ³ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice. | Hempel B et al. | β | 2023 | β |
| Effects of Intra-BLA Administration of PPAR Antagonists on Formalin-Evoked Nociceptive Behaviour, Fear-Conditioned Analgesia, and Conditioned Fear in the Presence or Absence of Nociceptive Tone in Rats. | Gaspar JC et al. | β | 2022 | β |
| Functional interactions between cannabinoids, omega-3 fatty acids, and peroxisome proliferator-activated receptors: Implications for mental health pharmacotherapies. | Jung T et al. | β | 2022 | β |
| Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine. | Greco R et al. | β | 2022 | β |
| The effects of fatty acid amide hydrolase inhibition and monoacylglycerol lipase inhibition on habit formation in mice. | Gianessi CA et al. | β | 2022 | β |
| Beta-caryophyllene inhibits cocaineΒ addiction-related behavior by activation of PPARΞ± and PPARΞ³: repurposing a FDA-approved food additive for cocaine use disorder. | Galaj E et al. | β | 2021 | β |
| Immune treatments for alcohol use disorder: A translational framework. | Meredith LR et al. | β | 2021 | β |
| <i>N-</i>Oleoylglycine and <i>N</i>-Oleoylalanine Do Not Modify Tolerance to Nociception, Hyperthermia, and Suppression of Activity Produced by Morphine. | Rock EM et al. | β | 2021 | β |
| N-Acylethanolamine Acid Amidase Inhibition Potentiates Morphine Analgesia and Delays the Development of Tolerance. | Congiu M et al. | β | 2021 | β |
| New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence. | Saravia R et al. | β | 2021 | β |
| Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders. | Sagheddu C et al. | β | 2021 | β |
| Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models. | Smith LC et al. | β | 2020 | β |
| D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction. | Mansouri E et al. | β | 2020 | β |
| Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation. | Butler K et al. | β | 2020 | β |
| Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for bingeΒ eating disorder. | Romano A et al. | β | 2020 | β |
| Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. | Matheson J et al. | β | 2020 | β |
| Enhancement of fear learning in PPARΞ± knockout mice. | Chikahisa S et al. | β | 2019 | β |
| Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward. | Sagheddu C et al. | β | 2019 | β |
| Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse. | Schmidt HD et al. | β | 2019 | β |
| N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. | Donvito G et al. | β | 2019 | β |
| Oleoylethanolamide restores alcohol-induced inhibition of neuronal proliferation and microglial activity in striatum. | Rivera P et al. | β | 2019 | β |
| Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats. | Petrie GN et al. | β | 2019 | β |
| Ξ<sup>9</sup>-Tetrahydrocannabinol During Adolescence Attenuates Disruption of Dopamine Function Induced in Rats by Maternal Immune Activation. | Lecca S et al. | β | 2019 | β |
| Fatty acid amide hydrolase (FAAH) inactivation confers enhanced sensitivity to nicotine-induced dopamine release in the mouse nucleus accumbens. | Pavon FJ et al. | β | 2018 | β |
| Hedonic Eating and the "Delicious Circle": From Lipid-Derived Mediators to Brain Dopamine and Back. | Coccurello R et al. | β | 2018 | β |
| Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse. | Orio L et al. | β | 2018 | β |
| Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARΞ± agonist) in smokers. | Gendy MNS et al. | β | 2018 | β |
| Attenuating Nicotine Reinforcement and Relapse by Enhancing Endogenous Brain Levels of Kynurenic Acid in Rats and Squirrel Monkeys. | Secci ME et al. | β | 2017 | β |
| Chronic FAAH inhibition during nicotine abstinence alters habenular CB1 receptor activity and precipitates depressive-like behaviors. | Simonnet A et al. | β | 2017 | β |
| Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels. | Rivera-Meza M et al. | β | 2017 | β |
| Hedonic eating in Prader-Willi syndrome is associated with blunted PYY secretion. | Rigamonti AE et al. | β | 2017 | β |
| InΒ vivo interactions between Ξ±7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-Ξ±: Implication for nicotine dependence. | Jackson A et al. | β | 2017 | β |
| Pioglitazone, a PPARΞ³ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. | Jones JD et al. | β | 2017 | β |
| Plasma concentrations of oleoylethanolamide and other acylethanolamides are altered in alcohol-dependent patients: effect of length of abstinence. | Garcia-Marchena N et al. | β | 2017 | β |
| The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats. | Haile CN et al. | β | 2017 | β |
| An association between the PPARΞ±-L162V polymorphism and nicotine dependency among patients with schizophrenia. | Nadalin S et al. | β | 2016 | β |
| An update on PPAR activation by cannabinoids. | O'Sullivan SE | β | 2016 | β |
| Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys. | Justinova Z et al. | β | 2016 | β |
| Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats. | Panlilio LV et al. | β | 2016 | β |
| Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics. | Ubaldi M et al. | β | 2016 | β |
| Impact of short access nicotine self-administration on expression of Ξ±4Ξ²2* nicotinic acetylcholine receptors in non-human primates. | Le Foll B et al. | β | 2016 | β |
| Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. | Perkins KA et al. | β | 2016 | β |
| Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. | Scherma M et al. | β | 2016 | β |
| Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg. | Tanda G | β | 2016 | β |
| Prenatal fat exposure and hypothalamic PPAR Ξ²/Ξ΄: Possible relationship to increased neurogenesis of orexigenic peptide neurons. | Chang GQ et al. | β | 2016 | β |
| Role of the satiety factor oleoylethanolamide in alcoholism. | Bilbao A et al. | β | 2016 | β |
| Sex differences in attenuation of nicotine reinstatement after individual and combined treatments of progesterone and varenicline. | Swalve N et al. | β | 2016 | β |
| Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults. | Rigamonti AE et al. | β | 2015 | β |
| Commonalities and Distinctions Among Mechanisms of Addiction to Alcohol and Other Drugs. | Ozburn AR et al. | β | 2015 | β |
| Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. | Justinova Z et al. | β | 2015 | β |
| Neurobiological Bases of Cue- and Nicotine-induced Reinstatement of Nicotine Seeking: Implications for the Development of Smoking Cessation Medications. | Stoker AK et al. | β | 2015 | β |
| Peroxisome proliferator-activated receptors Ξ± and Ξ³ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | β | 2015 | β |
| Role of the endogenous cannabinoid system in nicotine addiction: novel insights. | Gamaleddin IH et al. | β | 2015 | β |
| The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys. | Justinova Z et al. | β | 2015 | β |
| The Reinforcing Effects of Nicotine in Humans and Nonhuman Primates: A Review of Intravenous Self-Administration Evidence and Future Directions for Research. | Goodwin AK et al. | β | 2015 | β |
| The role of mesoaccumbens dopamine in nicotine dependence. | Balfour DJ | β | 2015 | β |
| Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats. | Lee AM et al. | β | 2014 | β |
| Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model. | Saha L et al. | β | 2014 | β |
| Changes in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training. | Bystrowska B et al. | β | 2014 | β |
| Dopamine D4 receptors in psychostimulant addiction. | Di Ciano P et al. | β | 2014 | β |
| Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans. | Robinson G et al. | β | 2014 | β |
| Role of cues and contexts on drug-seeking behaviour. | Perry CJ et al. | β | 2014 | β |
| Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats. | Sayd A et al. | β | 2014 | β |
| Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: therapeutic perspectives. | Melis M et al. | β | 2014 | β |
| AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. | Gamaleddin I et al. | β | 2013 | β |
| Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity. | PavΓ³n FJ et al. | β | 2013 | β |
| Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. | Panlilio LV et al. | β | 2013 | β |
| Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. | Simonnet A et al. | β | 2013 | β |
| Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARΞ± receptor-independent mechanism. | Bilbao A et al. | β | 2013 | β |
| Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. | Le Foll B et al. | β | 2013 | β |
| PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings. | Puligheddu M et al. | β | 2013 | β |
| PPARΞ± regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving Ξ±7 nicotinic acetylcholine receptors. | Melis M et al. | β | 2013 | β |
| Prior exposure to THC increases the addictive effects of nicotine in rats. | Panlilio LV et al. | β | 2013 | β |
| The endocannabinoid system and the brain. | Mechoulam R et al. | β | 2013 | β |
| The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. | Buczynski MW et al. | β | 2013 | β |
| Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. | Monteleone P et al. | β | 2012 | β |
| Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. | Melis M et al. | β | 2012 | β |
| Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. | Panlilio LV et al. | β | 2012 | β |
| The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. | Scherma M et al. | β | 2012 | β |
| Effects of endocannabinoid system modulation on cognitive and emotional behavior. | Zanettini C et al. | β | 2011 | β |
| Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. | Serrano A et al. | β | 2011 | β |
| Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease. | Johnston TH et al. | β | 2011 | β |
| The Endocannabinoid System as Pharmacological Target Derived from Its CNS Role in Energy Homeostasis and Reward. Applications in Eating Disorders and Addiction. | Viveros MP et al. | β | 2011 | β |
| The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. | Gamaleddin I et al. | β | 2011 | β |